메디채널

주메뉴 바로가기
본문 바로가기

기상청 제공

닫기

'김갑성' 기자의 전체기사

WuXi Biologics Singapore CRDMO Hub Advances with the Lau…

[ 메디채널 김갑성 기자 ] Innovative modular design will accelerate construction and manufacturing timelines, enabling rapid adaptation of manufacturing capacities across diverse product formats. Finished building will be one of the world's largest modular biologics Drug Product (DP) facilities, and will enhance WuXi Biologics' leadership in end-to-end DP capabilities. SINGAPORE, July 29, 2025 -- WuXi Biologics (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), announced construction has begun for a new modular Drug Product (DP) facility, wh
- 김갑성 기자
- 2025-07-29 16:00
Tigermed Completes Acquisition of Japanese CRO Micron

HANGZHOU, China and TOKYO, July 29, 2025 -- Tigermed (300347.SZ / 3347.HK), a leading global provider of clinical research solutions across the full lifecycle of global biopharmaceutical and medical device products, today announces the completion of its acquisition of CRO company Micron,Inc. Founded in 2005 and headquartered in Tokyo, Micron is a Japan-based Contract Research Organization (CRO) focusing in medical imaging and clinical trial services with over 160 employees. Micron brings nearly two decades of expertise in clinical research and the largest team of imaging expert
- 김갑성 기자
- 2025-07-29 13:37
Alphamab Oncology Announces Anti-HER2 Biparatopic ADC JS…

SUZHOU, China, July 29, 2025 -- Alphamab Oncology (stock code: 9966.HK) announced that anti-HER2 biparatopic antibody-drug conjugate (ADC) JSKN003 has been granted Orphan Drug Designation (ODD) by the U.S. Food and Drug Administration (FDA) for the treatment of gastric cancer and gastroesophageal junction cancer (GC/GEJ). GC/GEJ is the fifth most common cancer and the fifth leading cause of cancer death worldwide. According to the 2022 Global Cancer Statistics report released by the International Agency for Research on Cancer (IARC), a subsidiary of the World Health Organization, there
- 김갑성 기자
- 2025-07-29 10:37
Agilent and Nanyang Technological University's NEWRI Sign A…

SINGAPORE, July 29, 2025 -- Agilent Technologies Inc. (NYSE: A) announced the recent signing of a Memorandum of Understanding (MOU) with the Nanyang Environment & Water Research Institute (NEWRI), outlining their collaboration in advancing environmental and water research over the next three years. NEWRI is a leading research institute at Nanyang Technological University, Singapore (NTU Singapore), ranked 13th globally for Environmental Sciences by QS World University Ranking in 2025¹. The collaboration aims to further strengthen Singapore's capabilities in detecting e
- 김갑성 기자
- 2025-07-29 09:00
FROM THE ALZHEIMER'S ASSOCIATION INTERNATIONAL CONFERENCE 2025…

Key Takeaways Two lifestyle interventions in U.S. POINTER improved cognition in older adults at risk of cognitive decline. A structured intervention with more support and accountability showed greater improvement compared to a self-guided intervention. In a large, representative group of older adults at high risk for cognitive decline, multidomain lifestyle interventions were delivered with high adherence and safety. Cognitive benefits were consistent across age, sex, ethnicity, heart health status and apolipoprotein E-e4 genotype. TORONTO, July 29, 2025 -- The
- 김갑성 기자
- 2025-07-29 02:39
Siemens Healthineers Receives Frost & Sullivan's 2025 North Am…

[ 메디채널 김갑성 기자 ] Recognized for delivering diagnostic innovation, workflow efficiency, and enterprise imaging leadership through advanced visualization solutions SAN ANTONIO, July 28, 2025 -- Frost & Sullivan is pleased to announce that Siemens Healthineers has been awarded the 2025 North America Company of the Year Recognition in the advanced visualization applications industry for its outstanding achievements in diagnostic innovation, seamless platform integration, and customer impact. This recognition underscores Siemens Healthineers' market leadership in transforming medical i
- 김갑성 기자
- 2025-07-28 22:00
XellSmart Completed World's First Patient Dosing in its Registrati…

SUZHOU, China, July 28, 2025 -- XellSmart Biopharmaceutical (Suzhou/Shanghai) Co., Ltd. achieved a significant milestone in its "world's first" China NMPA & US FDA-approved registrational clinical trial. This Phase I China registrational clinical trial for XS228 Cell Injection – the world's first "off-the-shelf", allogeneic, iPSC-derived, spinal neural progenitor cell therapy targeting major neurological disorders, specifically spinal cord injury (SCI) – has commenced. The clinical trial initiation meeting was held at The Third Affiliated Hospital of Sun Yat-sen Univer
- 김갑성 기자
- 2025-07-28 21:10
World's First Engineered Exosome for Hair Growth & Localized…

SUZHOU, China, July 28, 2025 -- ImmVira Group ("ImmVira" or the "Company")recently announced that its engineered exosome products MVR-EX104 ("EX104", for alopecia treatment) and MVR-EX105 ("EX105", for localized fat accumulation) have obtained International Nomenclature of Cosmetic Ingredients (INCI) designations following review by the International Cosmetic Ingredient Nomenclature Committee (INC). This dual milestone underscores ImmVira's breakthrough leadership in functional aesthetic ingredients, bring forward revolutionary consumer healthca
- 김갑성 기자
- 2025-07-28 20:28
Alamar Biosciences Showcases Pioneering Brain-Derived p…

[ 메디채널 김갑성 기자 ] Groundbreaking Insights into Neurodegenerative Disease Biomarkers to be Unveiled through 30+ Posters and Presentations at International Meeting FREMONT, Calif., July 28, 2025 -- Alamar Biosciences, a company pioneering precision proteomics to drive the earliest detection of disease, today announced the presentation of NULISA™ data in over 30 scientific sessions and poster presentations at the AAIC conference held July 27-31 in Toronto, Canada. The NULISA platform is poised to redefine the landscape of biomarker detection, offering unprecedented sensitivity, specificit
- 김갑성 기자
- 2025-07-28 20:12
알라마 바이오사이언스, 알츠하이머 협회 국제학술대회(AAIC)에서 획기적인 뇌 유래 pTa…

[ 메디채널 김갑성 기자 ] 신경퇴행성 질환 바이오마커 연구의 새로운 지평 - 30개 이상의 포스터 및 프레젠테이션 통해 공개 프리몬트, 캘리포니아, 2025년 7월 28일 -- 정밀 단백체학을 기반으로 질병의 조기 진단을 선도하고 있는 알라마 바이오사이언스(Alamar Biosciences)가 자사의 NULISA™ 플랫폼 관련 데이터를 7월 27일부터 31일까지 캐나다 토론토에서 열리는 알츠하이머 협회 국제학술대회(Alzheimer's Association International Conference, AAIC)에서 30건 이상의 학술 세션과 포스터 발표를 통해 공개한다고 밝혔다. NULISA 플랫폼은 신경퇴행성 질환 진단 및 모니터링을 위한 바이오마커 검출 분야에서 감도, 특이성, 다중 분석 능력 측면에서 새로운 기준을 제시할 것으로 기대된다. 올해 AAIC에서는 NULISA를 사용하여 뇌유래 pTau와 120개 이상의 주요 중추신경계(CNS) 질환 관련 단백질에 대한 강력한 임상 데이터가 처음으로 공개된다. 이는 알츠하이머병 및 관련 신경퇴행성 질환의 조기 발견과 치료 모니터링을 가속화할 수 있는 중대한 성과로 평가된다.
- 김갑성 기자
- 2025-07-28 20:12

이전

81 82 83 84 85 86 87 88 89 90

많이 본 기사

최근기사

2025-10-20_MON

발행인 : 최희정 | 편집인 : 김갑성 |
등록번호: 서울특별시 아53302 | 등록일 2020-09-25 | 전화번호 02-565-7119 |
주소 : 서울특별시 강남구 영동대로 602, 6층 E115 (삼성동)
Copyright @메디채널 Corp. All rights reserved.

UPDATE: 2025년 10월 20일 09시 40분